Total Laparoscopic Hysterectomy Versus Total Abdominal Hysterectomy in Women With Endometrial Neoplasia
Total Laparoscopic Hysterectomy Versus Total Abdominal Hysterectomy in Women With Endometrial Neoplasia; Randomized Controlled Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Research Questions:
Is total laparoscopic hysterectomy associated with similar operative operative time as total abdominal hysterectomy and bilateral salpingoophrectomy in women with uterine neoplasia?
Research Hypothesis:
In women with uterine neoplasia TLH with BSO may be similar to TAH with BSO as regard operative time.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Ain Shams Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The presence of perimenopausal bleeding
- Early stage endometrial carcinoma.
- Endometrial hyperplasia with/without atypia.
Exclusion Criteria:
- Obese patients i.e., BMI< 29 k.g/m2.
- Patients unfit for laparoscopy as patients with cardio-pulmonary compromise.
- Presence of adnexal mass.
- End stage endometrial carcinoma stage 3 & 4.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Total Laparoscopic Hysterectomy
The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.
|
Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
|
|
Active Comparator: Total Abdominal hysterectomy
The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.
|
Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Operative time
Time Frame: From skin incision till closure of the vault "up to 4 hours".
|
Operative time measured in minutes using stopwatch excluding time of concomitant surgical procedures.
|
From skin incision till closure of the vault "up to 4 hours".
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood loss
Time Frame: From skin incision start until skin suturing is finished "up to 4 hours".
|
Intra operative blood loss will be estimated via:
|
From skin incision start until skin suturing is finished "up to 4 hours".
|
|
Blood transfusion
Time Frame: From admission to the hospital until the home discharge "up to 1 week".
|
The need to blood transfusion to the patient.
|
From admission to the hospital until the home discharge "up to 1 week".
|
|
Postoperative pain
Time Frame: 8 hours after the end of operation.
|
Assessment of pain intensity using Visual Analog Scale (VAS) which is one-dimensional measure of pain intensity. It is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. The scale is anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100). |
8 hours after the end of operation.
|
|
Hospital stay
Time Frame: From admission to the hospital until the home discharge "up to 1 week".
|
Hospital stay duration in days.
|
From admission to the hospital until the home discharge "up to 1 week".
|
|
Incidence of operative complications
Time Frame: During operation.
|
The need for laparotomy, and bowel or bladder or ureteric injury.
|
During operation.
|
|
Incidence of postoperative complications
Time Frame: Up to 1 week postoperative.
|
Morbidities e.g.:
|
Up to 1 week postoperative.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Walid E Mohammed, MD, Ain Shams Maternity Hospital
- Study Director: Mortada E Ahmed, MD, Ain Shams Maternity Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TLH-TAH-EN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.